Mazdutide
Highest phase reached
Phase 3
Drug type
Protein
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Protein
- Drug name
- Mazdutide
- ibi 362
- Ibi-362
- ibi362
- Ibi362
- IBI362
- ly 3305677
- LY-3305677
- ly3305677
- LY3305677
- mazdutida
- Mazdutida
- mazdutide
- Mazdutide
- mazdutide [INN]
- MAZDUTIDE [USAN]
- Mazdutide [WHO-DD]
- mazdutide inn
- mazdutide usan
- mazdutide who dd
- CAS registry numbers
- 2259884-03-0
- ChEMBL ID
- CHEMBL5095358
- FDA ingredient codes (UNII)
- MB76Z4IBZ5
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- mazdutide
- Type
- Peptide
- Drug name stem
- -tide
- Approval recorded by Guide to Pharmacology
- Yes
- Action
- Agonist
- Action type
- Agonist
- Target
- GLP-1 receptor
- Gene symbol
- GLP1R
- Protein identifier
- P43220
- Median affinity
- 7.64
- Affinity units
- pKi
- Action
- Agonist
- Action type
- Agonist
- Target
- glucagon receptor
- Gene symbol
- GCGR
- Protein identifier
- P47871
- Median affinity
- 7.84
- Affinity units
- pKi
- Action
- Full agonist
- Action type
- FULL_AGONIST
- Target
- GLP-1 receptor
- Gene symbol
- GLP1R
- Protein identifier
- P43220
- Median affinity
- 7.62
- Affinity units
- pEC50
- Action
- Full agonist
- Action type
- FULL_AGONIST
- Target
- glucagon receptor
- Gene symbol
- GCGR
- Protein identifier
- P47871
- Median affinity
- 8.14
- Affinity units
- pEC50
- Condition
- Diabetes Mellitus
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000400
- Subject identifier
- D003920
- Condition
- Obesity
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001073
- Subject identifier
- D009765
- Condition
- Kidney Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003086
- Subject identifier
- D007674
- Condition
- Non-alcoholic Fatty Liver Disease
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003095
- Subject identifier
- D065626
- Condition
- Diabetes Mellitus, Type 2
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005148
- Subject identifier
- D003924
- Condition identifier
- EFO_0000400
- Condition identifier
- EFO_0000660
- Condition identifier
- EFO_0001073
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003086
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003095
- Condition identifier
- HP_0000822
- Highest recorded phase
- 3
- Condition identifier
- HP_0001513
- Highest recorded phase
- 3
- Condition identifier
- HP_0025502
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0001627
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002046
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005015
- Condition identifier
- MONDO_0005148
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0007027
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007147
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0008487
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0011122
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0013209
- NCT03928379
- NCT04466904
- NCT04965506
- NCT05606913
- NCT05628311
- NCT04440345
- NCT04773977
- NCT04904913
- NCT05607680
- NCT05623839
- NCT05815680
- NCT05793450
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Sequence
- Type
- Protein
- Sequence
- HX1QGTFTSDYSKYLDEKKAX2EFVEWLLEGGPSSX3
- Component
- Modified residues
- Sequence
- X2(SMILES):CC(C)(N)C=O
- Component
- Modified residues
- Sequence
- X3(SMILES):NCC(N)=O
Related records
Trials (40)
- A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity
- A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）
- A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
- A Study of IBI362 9 mg in Chinese Adults With Obesity
- A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects
- A Study of IBI362 in Chinese Adolescents With Obesity or Overweight
- A Study of IBI362 in Chinese Patients With Type 2 Diabetes
- A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2
- A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- A Study of IBI362 in Participants With Obesity or Overweight
- A Study of IBI362 in Participants With Type 2 Diabetes
- A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
- A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity
- A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight
- A Study of LY3305677 in Healthy Participants
- A Study of LY3305677 in Participants With Obesity Or Overweight
- A Study of LY3305677 in Participants With Type 2 Diabetes
- A Study of Multiple Doses of LY3305677 in Healthy Participants
- A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
In development for (6)
- Alcohol abuse Phase 2
- Diabetes mellitus Phase 1
- Kidney disorder Phase 1
- Metabolic dysfunction-associated steatotic liver disease Phase 1
- Obesity disorder Phase 3
- Type 2 diabetes mellitus Phase 3
Other linked conditions (1)
- Polycystic ovary syndrome